269 related articles for article (PubMed ID: 25663410)
21. Angiopoietin-like proteins in multiple sclerosis.
Al-Temaimi R; Cherian P; Abu-Farha M; Alroughani R
J Neuroimmunol; 2019 May; 330():31-34. PubMed ID: 30784773
[TBL] [Abstract][Full Text] [Related]
22. Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.
Frisell T; Forsberg L; Nordin N; Kiesel C; Alfredsson L; Askling J; Hillert J; Olsson T; Piehl F
Mult Scler; 2016 Jan; 22(1):85-93. PubMed ID: 25921036
[TBL] [Abstract][Full Text] [Related]
23. Leukocyte adhesion molecule dynamics after Natalizumab withdrawal in Multiple Sclerosis.
Cobo-Calvo Á; Figueras A; Bau L; Matas E; Mañé Martínez MA; León I; Majòs C; Romero-Pinel L; Martínez-Yélamos S
Clin Immunol; 2016 Oct; 171():18-24. PubMed ID: 27496090
[TBL] [Abstract][Full Text] [Related]
24. Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.
Kaunzner UW; Kang Y; Monohan E; Kothari PJ; Nealon N; Perumal J; Vartanian T; Kuceyeski A; Vallabhajosula S; Mozley PD; Riley CS; Newman SM; Gauthier SA
Mult Scler Relat Disord; 2017 Jul; 15():27-33. PubMed ID: 28641769
[TBL] [Abstract][Full Text] [Related]
25. Natalizumab for multiple sclerosis: the dilemma of NOVA.
Hellwig K
Lancet Neurol; 2022 Jul; 21(7):579-581. PubMed ID: 35483388
[No Abstract] [Full Text] [Related]
26. Practice effect in Symbol Digit Modalities Test in multiple sclerosis patients treated with natalizumab.
Roar M; Illes Z; Sejbaek T
Mult Scler Relat Disord; 2016 Nov; 10():116-122. PubMed ID: 27919477
[TBL] [Abstract][Full Text] [Related]
27. Natalizumab induced cutaneous sarcoidosis-like reaction.
Durcan R; Heffron C; Sweeney B
J Neuroimmunol; 2019 Aug; 333():476955. PubMed ID: 31108403
[TBL] [Abstract][Full Text] [Related]
28. Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapy.
Sormani MP; De Stefano N
Neurology; 2014 Apr; 82(17):1484-5. PubMed ID: 24682968
[No Abstract] [Full Text] [Related]
29. The frequency of occurrence of atypical lymphocytes in peripheral blood smears of natalizumab-treated patients with multiple sclerosis.
Robier C; Amouzadeh-Ghadikolai O; Bregant C; Diez J; Melinz K; Quehenberger F; Quasthoff S
Int J Lab Hematol; 2017 Oct; 39(5):469-474. PubMed ID: 28481019
[TBL] [Abstract][Full Text] [Related]
30. Changes in brain atrophy indices in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
Arpín EC; Sobrino TG; Vivero CD; del Campo Amigo Jorrín M; Regal AR; González JP; Bouzas ML
Neurodegener Dis Manag; 2016; 6(1):5-12. PubMed ID: 26782312
[TBL] [Abstract][Full Text] [Related]
31. Natalizumab exposure during pregnancy in multiple sclerosis: a systematic review.
Peng A; Qiu X; Zhang L; Zhu X; He S; Lai W; Chen L
J Neurol Sci; 2019 Jan; 396():202-205. PubMed ID: 30502611
[No Abstract] [Full Text] [Related]
32. Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy.
Castellazzi M; Bellini T; Trentini A; Delbue S; Elia F; Gastaldi M; Franciotta D; Bergamaschi R; Manfrinato MC; Volta CA; Granieri E; Fainardi E
Dis Markers; 2016; 2016():8434209. PubMed ID: 27340316
[TBL] [Abstract][Full Text] [Related]
33. [Natalizumab treatment in multiple sclerosis].
Tanaka M
Rinsho Shinkeigaku; 2015; 55(8):537-43. PubMed ID: 26156254
[TBL] [Abstract][Full Text] [Related]
34. Natalizumab discontinuation: an increasingly tricky proposition.
West TW; Killestein J; Fox RJ
Eur J Neurol; 2012 May; 19(5):663-4. PubMed ID: 22054207
[No Abstract] [Full Text] [Related]
35. Three cases of herpes zoster radiculitis in MS patients treated with natalizumab.
Yamout BI; Abou Zeid N; Taha AJ; Zeineddine MM; Khoury SJ
Mult Scler Relat Disord; 2016 Sep; 9():122-4. PubMed ID: 27645358
[TBL] [Abstract][Full Text] [Related]
36. Novel Agents for Relapsing Forms of Multiple Sclerosis.
Straus Farber R; Harel A; Lublin F
Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285
[TBL] [Abstract][Full Text] [Related]
37. Natalizumab is effective in controlling the inflammatory rebound after its discontinuation and failure of an alternative treatment.
Barroso B; Miquel M; Marasescu R; Demasles S; Krim E; Bonnan M
Mult Scler Relat Disord; 2015 Jul; 4(4):380-2. PubMed ID: 26195060
[TBL] [Abstract][Full Text] [Related]
38. Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab.
Fagius J; Feresiadou A; Larsson EM; Burman J
Mult Scler Relat Disord; 2017 Feb; 12():82-87. PubMed ID: 28283113
[TBL] [Abstract][Full Text] [Related]
39. Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab.
Stosic M; De Jesus P; McCarthy J; Hutton G; Rivera V
Neurology; 2011 Aug; 77(5):505-7. PubMed ID: 21775738
[No Abstract] [Full Text] [Related]
40. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
Vennegoor A; Rispens T; Strijbis EM; Seewann A; Uitdehaag BM; Balk LJ; Barkhof F; Polman CH; Wolbink G; Killestein J
Mult Scler; 2013 Apr; 19(5):593-600. PubMed ID: 22992450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
